Celldex Therapeutics(CLDX)
HAMPTON, NJ
BiotechnologyFocus: Small Molecules, Biologics, Vaccines
Celldex Therapeutics is a life sciences company focused on Small Molecules, Biologics, Vaccines.
Infectious DiseasesVaccines
Funding Stage
PUBLIC
Employees
501-1000
Open Jobs
0
Pipeline & Clinical Trials
glembatumumab vedotin
Metastatic gpNMB Expressing Triple Negative Breast CancerClinical Trials (1)
NCT03067935Individual Patient Expanded Access-Glembatumumab Vedotin
N/Arindopepimut
Recurrent GBMClinical Trials (1)
NCT03068650Expanded Access (Compassionate Use) Treatment Protocol Rindopepimut
N/ATCR-transduced T cells
Malignant Epithelial NeoplasmsClinical Trials (1)
NCT05349890Personalized TCR-T: Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T)
Phase 1CDX-585
Non-small Cell Lung CancerClinical Trials (1)
NCT05788484A Study of CDX-585 in Patients With Advanced Malignancies
Phase 1CDX-0159
Cold UrticariaClinical Trials (1)
NCT04548869A Single Dose Study of the Safety, Pharmacokinetics and Pharmacodynamics of CDX-0159 in Patients With Cold Contact Urticaria, Symptomatic Dermographism, or Cholinergic Urticaria
Phase 1Clinical Trials (1)
NCT01460134A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers
Phase 1DEC-205/NY-ESO-1 Fusion Protein CDX-1401
Acute Myeloid LeukemiaClinical Trials (1)
NCT03358719DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
Phase 1CDX-301
HealthyClinical Trials (1)
NCT01465139A Study to Evaluate CDX-301 (rhuFlt3L) in Healthy Volunteers
Phase 1CDX-0159
Healthy SubjectsClinical Trials (1)
NCT05031624A Phase 1 Study of Subcutaneous CDX-0159 in Healthy Subjects
Phase 1Combination of Varlilumab and Atezolizumab
Carcinoma, Renal CellClinical Trials (1)
NCT02543645A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer
Phase 1CDX-622
Healthy ParticipantsClinical Trials (1)
NCT06650761A Phase I Study of CDX-622
Phase 1odetiglucan
Metastatic Pancreatic AdenocarcinomaClinical Trials (1)
NCT05484011A Maintenance Therapy Study of Odetiglucan With CDX-1140 in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
Phase 1CDX-0159
Chronic Spontaneous UrticariaClinical Trials (1)
NCT04538794A Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria
Phase 1CDX-301
MelanomaClinical Trials (1)
NCT04930783NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma
Phase 1Phase 1
Clinical Trials (1)
NCT02473731A Window of Opportunity Study of KTN3379 in Surgically Resectable Head and Neck Cancer Patients
Phase 1KTN3379
Thyroid CancerClinical Trials (1)
NCT02456701Enhancing Radioiodine Incorporation Into BRAF Mutant Thyroid Cancers With the Combination of Vemurafenib and KTN3379
Phase 1CDX-014
Renal Cell Carcinoma (RCC)Clinical Trials (1)
NCT02837991A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell Carcinoma and Ovarian Clear Cell Carcinoma
Phase 1CDX-1307
Breast CancerClinical Trials (1)
NCT00648102Phase I Study of CDX-1307, hCG-B Vaccine, for Patients With Incurable, Locally Advanced or Metastatic Breast, Colorectal, Pancreatic, Bladder or Ovarian Cancer
Phase 1CDX-1135
Dense Deposit DiseaseClinical Trials (1)
NCT01791686Clinical Trial of CDX-1135 in Pediatric and Adult Patients With Dense Deposit Disease
Phase 1CDX1127
Prostatic NeoplasmsClinical Trials (1)
NCT02284971Pilot Study of SBRT and CDX-1127 in Prostate Cancer
Phase 1CDX-0159
Prurigo NodularisClinical Trials (1)
NCT04944862A Study of CDX-0159 in Patients With Prurigo Nodularis
Phase 1CDX-527
Non-small Cell Lung CancerClinical Trials (1)
NCT04440943A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies
Phase 1CDX-622
Mild to Moderate AsthmaClinical Trials (1)
NCT07330778A Study of CDX-622 in Participants With Mild to Moderate Asthma
Phase 1CDX-0159
Healthy SubjectsClinical Trials (1)
NCT04146129A Phase 1 Study of CDX-0159
Phase 1PLD Chemotherapy
HER2-negative Breast CancerClinical Trials (1)
NCT05029999CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer
Phase 1CDX-1140
MelanomaClinical Trials (1)
NCT03329950A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies
Phase 1KTN3379
Advanced CancerClinical Trials (1)
NCT02014909A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors
Phase 1ONT-10, Varlilumab combination
Advanced Breast CarcinomaClinical Trials (1)
NCT02270372Study of ONT-10 and Varlilumab to Treat Advanced Ovarian or Breast Cancer
Phase 1Glembatumumab Vedotin
Triple Negative Breast CancerClinical Trials (1)
NCT03473691Pilot Study of Glembatumumab Vedotin Following Doxorubicin and Cytoxan as Neo-adjuvant Therapy in Gp-NMB-expressing High Risk Triple Negative Breast Cancer
Phase 1CDX1307
Breast CancerClinical Trials (1)
NCT00709462A Study of CDX-1307, in Patients With Incurable Breast, Colorectal, Pancreatic, Ovarian or Bladder Cancer (CDX 1307-01)
Phase 1CDX-0158
Advanced CancerClinical Trials (1)
NCT02642016A Study to Evaluate the Safety and Pharmacokinetics of CDX-0158 in Adult Patients With Advanced Solid Tumors
Phase 1Phase 1
Combination of varlilumab and sunitinib
Carcinoma, Renal CellClinical Trials (1)
NCT02386111A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma
Phase 1IMA950
GliomaClinical Trials (1)
NCT02924038A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG)
Phase 1Varlilumab
B Cell LymphomaClinical Trials (1)
NCT03307746A Combination of Rituximab and Varlilumab Immunotherapy in Patients with B-cell Lymphoma
Phase 1/2CR011-vcMMAE
Unresectable Stage III or Stage IV MelanomaClinical Trials (1)
NCT00412828A Phase I/II Study of CR011-vcMMAE in Subjects With Unresectable Stage III or Stage IV Melanoma
Phase 1/2Pembrolizumab
Non-Hodgkin's LymphomaClinical Trials (1)
NCT03789097Vaccination With Flt3L, Radiation, and Poly-ICLC
Phase 1/26MHP
MelanomaClinical Trials (1)
NCT04364230Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma)
Phase 1/2Trametinib daily Until PD
MelanomaClinical Trials (1)
NCT03580382Study of CDX-3379, a Human Monoclonal Antibody Targeting ERBB3, in Combination With the MEK Inhibitor, Trametinib, in Patients With Advanced Stage NRAS Mutant and BRAF/NRAS Wildtype (WT) Melanoma
Phase 1/2CR011-vcMMAE
Breast CancerClinical Trials (1)
NCT00704158Study of CR011-vcMMAE to Treat Locally Advanced or Metastatic Breast Cancer
Phase 1/26MHP
MelanomaClinical Trials (1)
NCT03617328Vaccination With 6MHP, With or Without Systemic CDX-1127, in Patients With Stage II-IV Melanoma
Phase 1/2Combination of varlilumab and ipilimumab
Unresectable Stage III or Stage IV MelanomaClinical Trials (1)
NCT02413827A Study of Varlilumab (Anti-CD27) and Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or IV Melanoma
Phase 1/2FLT3 Ligand
Non Small Cell Lung CancerClinical Trials (1)
NCT04491084FLT3 Ligand, CD40 Agonist Antibody, and Stereotactic Radiotherapy
Phase 1/2DEC-205/NY-ESO-1 Fusion Protein CDX-1401
Fallopian Tube CarcinomaClinical Trials (1)
NCT02166905DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission
Phase 1/2rhuFlt3L/CDX-301
Low-Grade B-cell LymphomaClinical Trials (1)
NCT01976585In Situ Vaccine for Low-Grade Lymphoma: Combination of Intratumoral Flt3L and Poly-ICLC With Low-Dose Radiotherapy
Phase 1/2Combination of varlilumab and nivolumab
Squamous Cell Carcinoma of the Head and Neck (SCCHN)Clinical Trials (1)
NCT02335918A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors
Phase 1/2Phase I: Glembatumumab Vedotin
Squamous Cell Carcinoma of the LungClinical Trials (1)
NCT02713828Study of Glembatumumab Vedotin in gpNMB-Expressing, Advanced or Metastatic SCC of the Lung
Phase 1/2CDX-1401 in combination with Resiquimod and/or Poly-ICLC
Advanced MalignanciesClinical Trials (1)
NCT00948961A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1
Phase 1/2CDX-301
Pancreatic CancerClinical Trials (1)
NCT04536077Immunologic Effects of CDX-301 and CDX-1140 in Resectable Pancreatic Cancer Patients
Phase 2Barzolvolimab
Atopic DermatitisClinical Trials (1)
NCT06727552A Study of Barzolvolimab in Patients With Atopic Dermatitis
Phase 2Open Jobs (0)
No open positions listed yet. Check their careers page directly.
Interview Prep Quick Facts
Founded: 2017
Portfolio: 72 clinical trials
Top TAs: Oncology, Nephrology
SEC Filings: 2 available
Financials (FY2025)
Revenue
$7M192%
R&D Spend
$118M(1715%)43%
Net Income
-$141MCash
$28M